We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+10.98%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$40.7B
AUM Growth
-$4.56M
(-0.01%)
Cap. Flow
-$3.46B
Cap. Flow
% of AUM
-8.5%
Top 10 Holdings %
Top 10 Hldgs %
19.9%
Holding
801
New
88
Increased
169
Reduced
396
Closed
90
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$165M |
| 2 |
Costco
COST
|
+$134M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$126M |
| 4 |
Johnson Controls International
JCI
|
+$121M |
| 5 |
3M
MMM
|
+$112M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.48B |
| 2 |
Apple
AAPL
|
+$136M |
| 3 |
Marathon Petroleum
MPC
|
+$123M |
| 4 |
CenterPoint Energy
CNP
|
+$123M |
| 5 |
Under Armour
UAA
|
+$117M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.42% |
| 2 | Healthcare | 16.85% |
| 3 | Financials | 12.9% |
| 4 | Consumer Discretionary | 10.95% |
| 5 | Industrials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
PVH
PVH
$4B
| $9.07M | 0.02% |
86,300
-1,105,100
| -93% | -$105M |
|
|
TECX
552
Tectonic Therapeutic
TECX
$529M
| $9.06M | 0.02% |
37,500
| – | – |
|
|
CTXS
553
DELISTED
Citrix Systems Inc
CTXS
| $9.03M | 0.02% |
81,400
-69,300
| -46% | -$7.46M |
|
|
LOGC
554
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
| $8.97M | 0.02% |
1,246,554
-131,921
| -10% | -$1.19M |
|
|
KALV
555
DELISTED
KalVista Pharmaceuticals
KALV
| $8.9M | 0.02% |
500,000
-200,000
| -29% | -$2.61M |
|
|
DRNA
556
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $8.81M | 0.02% |
400,000
-2,150,000
| -84% | -$43.3M |
|
557
Clarivate
CLVT
$1.27B
| $8.65M | 0.02% |
515,000
+165,000
| +47% | +$2.78M |
|
|
ARNA
558
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $8.63M | 0.02% |
190,000
| – | – |
|
559
STMicroelectronics
STM
$46.7B
| $8.5M | 0.02% |
315,800
-116,000
| -27% | -$2.74M |
|
560
Newell Brands
NWL
$2.38B
| $8.4M | 0.02% |
437,200
+278,900
| +176% | +$5.37M |
|
|
NLSN
561
DELISTED
Nielsen Holdings plc
NLSN
| $8.37M | 0.02% |
412,394
-15,769
| -4% | -$320K |
|
562
Robert Half
RHI
$3.87B
| $8.27M | 0.02% |
131,000
+18,500
| +16% | +$1.07M |
|
563
Kosmos Energy
KOS
$1.6B
| $8.27M | 0.02% |
1,450,000
| – | – |
|
564
Iron Mountain
IRM
$36.4B
| $8.08M | 0.02% |
253,652
-40,900
| -14% | -$1.34M |
|
565
Regions Financial
RF
$26.4B
| $8.07M | 0.02% |
470,564
-803,400
| -63% | -$13.2M |
|
566
JetBlue
JBLU
$2.28B
| $8.07M | 0.02% |
431,221
+75,000
| +21% | +$1.39M |
|
567
DaVita
DVA
$15.4B
| $7.89M | 0.02% |
105,200
+70,500
| +203% | +$4.68M |
|
|
PRVL
568
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $7.85M | 0.02% |
496,169
-16,000
| -3% | -$204K |
|
569
Xerox
XRX
$387M
| $7.85M | 0.02% |
+213,000
| New | +$7.45M |
|
570
EQT Corp
EQT
$33.3B
| $7.81M | 0.02% |
+716,340
| New | +$7.01M |
|
571
HBT Financial
HBT
$1.3B
| $7.79M | 0.02% |
+410,000
| New | +$6.99M |
|
|
MYOV
572
DELISTED
Myovant Sciences Ltd.
MYOV
| $7.76M | 0.02% |
+500,000
| New | +$5.04M |
|
573
A.O. Smith
AOS
$8.17B
| $7.63M | 0.02% |
160,232
-86,001
| -35% | -$4.17M |
|
574
Revvity
RVTY
$12.6B
| $7.59M | 0.02% |
78,160
-166,100
| -68% | -$14.8M |
|
575
Avient
AVNT
$3.33B
| $7.36M | 0.02% |
+200,000
| New | +$6.53M |
|
Similar funds
Adage Capital Partners's Q4 2019 Portfolio in Review
As of Q4 2019, Adage Capital Partners held 801 positions worth $40.7B, down 0.01% from $40.7B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Adage Capital Partners withdrew a net $3.46B in Q4 2019, closing 90 positions and reducing 396 holdings. Its most notable exit was Celgene Corp, an estimated $1.48B position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Bristol-Myers Squibb worth $142M.
- Adage Capital Partners's largest Q4 2019 buy was Bristol-Myers Squibb: 2,207,539 shares worth $142M.
- Adage Capital Partners added most to RTX Corp in Q4 2019, an estimated $165M increase.
- Adage Capital Partners's biggest Q4 2019 reduction was Apple, cutting an estimated $136M.
- Adage Capital Partners fully exited Celgene Corp in Q4 2019, selling an estimated $1.48B.
- Adage Capital Partners's ten largest holdings make up 20% of its $40.7B portfolio in Q4 2019.
- Adage Capital Partners opened 88 new positions and closed 90 in Q4 2019.
- Adage Capital Partners's portfolio value fell 0.01% quarter-over-quarter to $40.7B.
Based on Adage Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.